ZYNE Loses Shine, ESPR To Report Data In Q2, NVLN Touches New Low

The following are some of today’s top losers in the pharma/biotech sector.

1. Zynerba Pharmaceuticals Inc. (ZYNE)

Lost 11.15% to close Wednesday’s trading at $11.56. The stock has lost nearly 21% in the last three days.

News: No news

Recent event:

— On December 3, 2017, the Company presented new data from the completed phase II STAR 1 study and ongoing STAR 2 18-month open label extension study evaluating ZYN002 cannabidiol (CBD) transdermal gel in patients with focal seizures.

According to the results, patients who received ZYN002 (195mg during STAR 1 for three months and 390mg for six months in STAR 2) for a total of nine months achieved a median reduction in seizures of 65%. Patients who received ZYN002 (390mg for three months in STAR 1 and six months in STAR 2) achieved a 48% median reduction in seizures from baseline.

Top line results from the STAR 1 study, reported in August of this year, showed that ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period for either the high or low dose cohorts. (97.5 mg or 195 mg).

The Company is planning a phase II trial of ZYN002 in epilepsy based on the new data.

2. Mersana Therapeutics Inc. (MRSN)

Lost 10.49% to close Wednesday’s trading at $15.79.

News: No news

Recent event:

— The Company went public on the NASDAQ Global Select Market on June 28, 2017 at an offering price of 15.00 per share.

Near-term catalysts:

— Interim safety results from phase I trial of lead oncology drug candidate XMT-1522 in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer are expected around the end of this year.
— Begin phase I dose escalation study of XMT-1536, a potential first-in-class Dolaflexin ADC targeting NaPi2b-expressing tumors, in early 2018.

3. Esperion Therapeutics Inc. (ESPR)

Lost 9.39% to close Wednesday’s trading at $53.14.

News: No news

Clinical trials & Near-term catalysts:

The Company’s lead drug candidate is Bempedoic acid, a once-daily, oral LDL-C lowering drug that significantly reduces elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.

Bempedoic acid is under a global pivotal phase III program consisting of 4 studies – Studies 1, 2, 3, 4.

Top-line results from Studies 1, 3 and 4 are expected in the second quarter of 2018, with top-line results from Study 2 expected in the third quarter of 2018.

A pivotal…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *